GNMSF (Genmab AS) FCF Margin % : 38.98% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Genmab AS FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genmab AS's Free Cash Flow for the three months ended in Dec. 2024 was $353 Mil. Genmab AS's Revenue for the three months ended in Dec. 2024 was $904 Mil. Therefore, Genmab AS's FCF Margin % for the quarter that ended in Dec. 2024 was 38.98%.

As of today, Genmab AS's current FCF Yield % is 9.41%.

The historical rank and industry rank for Genmab AS's FCF Margin % or its related term are showing as below:

GNMSF' s FCF Margin % Range Over the Past 10 Years
Min: 15.54 Med: 24.13 Max: 63.42
Current: 34.67

During the past 13 years, the highest FCF Margin % of Genmab AS was 63.42%. The lowest was 15.54%. And the median was 24.13%.

GNMSF's FCF Margin % is ranked better than
94.54% of 1008 companies
in the Biotechnology industry
Industry Median: -127.825 vs GNMSF: 34.67

Genmab AS FCF Margin % Historical Data

The historical data trend for Genmab AS's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS FCF Margin % Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

60.59

23.48

24.78

42.52

34.69

Genmab AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															33.73	35.84	27.51	35.83	38.98

Competitive Comparison of Genmab AS's FCF Margin %

For the Biotechnology subindustry, Genmab AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Genmab AS's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Genmab AS FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Genmab AS's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	1048.427	/	3022.423
	=	34.69 %

Genmab AS's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	352.565	/	904.368
	=	38.98 %

Genmab AS FCF Margin % Related Terms

Thank you for viewing the detailed overview of Genmab AS's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.